#TalkingRegMed 7: Cell therapy and big pharma with Sven Kili, GSK
In this exclusive video, Sven Kili, ŽVP and Head of Cell & Gene Therapy Development, GSK, explains why rare diseases are so amenable to treatment with cell therapies.
In the latest episode of TalkingRegMed, Sven Kili, ŽVP and Head of Cell & Gene Therapy Development, GSK, explains why rare diseases are so amenable to treatment with cell therapies. Filmed at GSK House (UK), Sven also discusses why big pharma is increasingly involved in the cell therapy and regenerative medicine industry.
Find out more: